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AbsTrACT
background Our understanding of the acquisition of 
intestinal mucosal immunity and the control of poliovirus 
replication and transmission in later life is still emerging.
Methods As part of a 2011 randomised, blinded, placebo-
controlled clinical trial of the experimental antiviral agent 
pocapavir (EudraCT 2011-004804-38), Swedish adults, 
aged 18–50 years, who had previously received four 
doses of inactivated polio vaccine (IPV) in childhood 
were challenged with a single dose of monovalent oral 
polio vaccine type 1 (mOPV1). Using faecal samples 
collected before and serially, over the course of 45 days, 
after mOPV1 challenge from a subset of placebo-arm 
participants who did not receive pocapavir (N=12), we 
investigated the kinetics of the intestinal antibody response 
to challenge virus by measuring poliovirus type 1-specific 
neutralising activity and IgA concentrations.
results In faecal samples collected prior to mOPV1 
challenge, we found no evidence of pre-existing intestinal 
neutralising antibodies to any of the three poliovirus 
serotypes. Despite persistent high-titered vaccine virus 
shedding and rising serum neutralisation responses after 
mOPV1 challenge, intestinal poliovirus type 1-specific 
neutralisation remained low with a titer of ≤18.4 across 
all time points and individuals. Poliovirus types 1-specific, 
2-specific and 3-specific IgA remained below the limit of 
detection for all specimens collected postchallenge.
Interpretation In contrast to recent studies demonstrating 
brisk intestinal antibody responses to oral polio vaccine 
challenge in young children previously vaccinated with IPV, 
this investigation finds that adults previously vaccinated 
with IPV have only modest intestinal poliovirus type 
1-specific neutralisation and no IgA responses that are 
measurable in stool samples following documented mOPV1 
infection.
InTroduCTIon
To achieve global polio eradication, we 
must halt the transmission of all poliovi-
ruses. Vaccines that induce robust intes-
tinal neutralising immune responses and 
interrupt poliovirus replication on mucosal 
surfaces continue to serve as the essential 
tools for realising this goal.1 2 Nevertheless, 
the magnitude of mucosal immunity that can 
be induced by vaccination is highly heteroge-
neous and can be modulated by the type and 
timing of the delivered vaccine schedule3–5 as 
Key questions
What is already known?
 ► Although highly effective at protecting individuals 
from paralytic poliomyelitis, a childhood immuni-
sation schedule based on inactivated polio vaccine 
(IPV) has a limited ability to inhibit intestinal viral 
replication on subsequent exposure to either live 
vaccine virus or circulating wild-type virus.
 ► Recent trials have demonstrated that infants chal-
lenged with live oral poliovirus vaccine following 
primary series with IPV rapidly develop intestinal 
poliovirus-specific neutralising antibody responses 
that are associated with reduced enteric viral rep-
lication. The impact of oral poliovirus vaccine chal-
lenge on intestinal poliovirus-specific neutralising 
antibody responses in adults is unknown.
What are the new findings?
 ► In contrast to studies conducted in infants, adults 
who received IPV in early childhood did not devel-
op intestinal antibody responses on challenge with 
monovalent oral polio vaccine type 1.
What do the new findings imply?
 ► This study raises concern that adults are unlikely 
to mount intestinal antibody responses that protect 
against viral replication and shedding on exposure to 
live polio vaccine in later life.
 ► These findings imply that existing oral polio vac-
cines may be less effective at inducing transmis-
sion-blocking intestinal antibody responses in adults 
than they are in children.
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well as recipient-specific characteristics, including factors 
related to the environment6 and enteric virome.7 8
Today, >50 years of scientific research confirm that 
live-attenuated oral polio vaccines (OPVs) administered 
in childhood are capable of stimulating the production 
of poliovirus-specific neutralising antibodies in naso-
pharyngeal and gastrointestinal mucosal tissues9–12 and 
thereby inhibiting poliovirus replication on subsequent 
homologous OPV challenge.13–15 In contrast, current 
evidence suggests childhood immunisation schedules 
based exclusively on inactivated (killed) polio vaccines 
(IPVs) induce only negligible intestinal immunity3 9 11 16 
and fail to interrupt viral replication on subsequent expo-
sure to either vaccine virus14 17 18 or circulating wild-type 
viruses.19–21
Potential interactions between OPV and IPV in the 
context of mucosal immunity remains an area of active 
inquiry. Several studies have suggested that paediatric 
OPV schedules (ie, OPV-first schedules) may educate 
the intestinal immune system such that a supplemental 
late dose of IPV may significantly boost children’s preex-
isting mucosal neutralising activity.5 22 23 On the other 
hand, a series of recent trials in Latin American infants 
have demonstrated that children who instead received 
primary vaccine series with IPV (ie, IPV-first schedules) 
shed high quantities of vaccine virus after receiving a 
supplemental challenge dose of OPV,17 18 but consistently 
developed strong poliovirus type-specific enteric neutral-
ising activity by 2 weeks’ post-OPV challenge.11 12
We hypothesised that, like their paediatric counter-
parts, adults whose only known poliovirus experience 
was IPV receipt in early childhood would have limited 
intestinal immunity at baseline, but would develop robust 
intestinal antibody responses when challenged with a live 
OPV. As part of a 2011 randomised clinical trial of the 
experimental antiviral agent pocapavir, Swedish adults 
who had exclusively received IPV in childhood were 
challenged with a single dose of monovalent oral polio 
vaccine type 1 (mOPV1). The primary results of the trial 
by Collett and colleagues demonstrate an antiviral effect 
of pocapavir, but also described mOPV1 shedding in the 
placebo-arm participants (N=48) with a median dura-
tion of virus excretion of 13 days.24 To investigate the 
impact of this sustained viral replication on the acqui-
sition of mucosal immunity in adults, we assayed faecal 
samples collected serially after mOPV1 challenge from 
a randomly selected subset of the placebo-arm partici-
pants. The kinetics of the type 1-specific intestinal anti-
body response to mOPV1 challenge virus in adults were 
evaluated by measuring poliovirus type-specific neutral-
ising activity and IgA concentrations in stool samples.
MeTHods
study design and participants
The design and primary outcomes of the phase I, 
randomised, blinded, placebo-controlled trial under-
taken between 10 January and 18 December 2012 have 
been described previously.24 The study protocol is avail-
able at: https://www. clin ical tria lsre gister. eu/ ctr- search/ 
trial/ 2011- 004804- 38/ SE. Trial participants included 
healthy Swedish volunteers, aged 18–50 years, who had 
received the recommended Swedish childhood vaccina-
tion schedule of four IPV injections.24 Individuals were 
screened for prior exposure to live poliovirus, and indi-
viduals both positive for total serum IgA and negative for 
poliovirus-specific serum IgA were eligible for participa-
tion.
For the trial, all participants were challenged with a 
single dose of mOPV1 (median cell culture infective dose 
(CCID50), 10
6) and then followed for 45 days. Faecal spec-
imens were collected from all participants prior to the 
mOPV1 challenge and serially thereafter. Blood samples 
were collected at baseline and on the last day of the 
study. In the current analyses, a subset of twelve partici-
pants were selected at random from the 48 placebo-arm 
controls for further analysis of the intestinal antibody 
response. Depending on the trial arm, subjects received 
either a standard (fat content, <25 g) or a high-fat meal 
(fat content, 60–75 g) over the course of the 14-day 
placebo administration period.
Laboratory procedures
Stool samples collected from the study participants and 
stored frozen at the National Institute for Public Health 
and the Environment (Bilthoven, The Netherlands) were 
identified, thawed, aliquoted and refrozen prior to ship-
ping to the USA.10 11 15 25 This excluded any possibility of 
chloroform treatment, which is used in virus titration but 
has been previously shown to inactivate antibody activity 
(Wright laboratory, unpublished data). At Dartmouth 
Geisel School of Medicine (Hanover, New Hampshire, 
USA), investigators evaluated intestinal mucosal immu-
nity by measuring poliovirus-specific neutralising activity 
and IgA in stool samples. As previously described, polio-
virus type-specific neutralising activity was determined by 
limiting dilution inhibition of luciferase-expressing wild 
type-derived polio pseudoviruses in vitro and presented 
as the reciprocal of the highest sample dilution needed 
to achieve 60% neutralisation as compared with control 
wells with no added sample.25 Poliovirus-specific stool 
neutralisation titers of less than two were considered 
undetectable and recorded as one. In an effort to deter-
mine if any other pathogen-specific mucosal antibodies 
could be quantified in the stool specimens of these 
adults, investigators also measured intestinal neutralising 
activity to respiratory syncytial virus (RSV) and A/Cali-
fornia/04/2009 H1N1 influenza using luciferase-based 
assays, similar to that used for poliovirus, in the stool 
samples collected 45 days’ postchallenge. Specifically, 
stool extracts were tested for RSV neutralisation in micr-
otiter assays using a recombinant RSV-Renilla luciferase 
(rA2-Rluc) virus in HEp-2 target cells and based on previ-
ously published methods.26 Neutralisation of influenza 
was evaluated in Madin-Darby Canine Kidney (MDCK 
NBL-2) cells infected with A/California/04/2009 H1N1 
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Figure 1 Monovalent oral polio vaccine type 1 viral 
shedding (log10 CCID50 per gram of stool) in the 4 weeks 
following challenge among the 12 placebo-arm participants 
in the study sample.
virus (CA/09) encoding NanoLuc (NLuc) luciferase as 
described.27 Samples were serially diluted twofold prior 
to incubation with virus and then added to target cells. 
Luciferase expression was quantified in cell lysates after 
24 hours at 37°C, using either the Renilla or NanoGlo 
Luciferase assay systems (Promega, Madison, Wisconsin, 
USA) for RSV and influenza, respectively. Relative light 
units were measured on a BioTek Synergy 2 microplate 
reader (Winooski, Vermont, USA). Neutralisation was 
again calculated as the reciprocal of the highest sample 
dilution to yield a 60% reduction in relative light units. 
Total and poliovirus type-specific concentrations of IgA 
in stool specimens were quantified, relative to a serum 
standard, using a multiplex Luminex-based microsphere 
assay developed by coupling monovalent IPVs to fluores-
cently coded magnetic microspheres.15 As described in 
the parent study, the quantification of type-specific serum 
antibody titers and mOPV1 viral shedding was performed 
at the National Institute for Public Health and the Envi-
ronment using standard methods.5 24 Serum neutralisa-
tion titers less than eight were recorded as four.
statistical analysis
Longitudinal patterns in shedding and immune markers 
were evaluated by plotting viral shedding titers and 
poliovirus type-specific serum IgA and stool neutralisa-
tion titers by the days since mOPV1 challenge. Wilcoxon 
signed rank tests were used to compare type 1-specific 
serum neutralisation prechallenge and postchallenge. 
Distributions of virus-specific IgA in stool samples 45 
days’ postchallenge were compared using column scatter 
graphs. All p values are from two-sided statistical tests, 
and all analyses were performed using Stata V.15.0 and 
R V.3.2.5.
Patient and public involvement
Patients and the public were not involved in our work.
ethics and role of the funding source
The study was approved by the Göteborg Regional 
Ethical Review Board (2011-004804-38; 151:2012/62373) 
and was conducted in accordance with the Declaration 
of Helsinki, the International Conference on Harmo-
nisation guidelines for Good Clinical Practice, and the 
codes and regulation of the USA and Sweden regarding 
research on human subjects. ASB and JFM are employees 
of the study funder and were involved in study design, 
data interpretation and writing of the report. The funder 
had no role in data collection. All authors had full access 
to the data in the study and share final responsibility for 
the decision to submit for publication.
resuLTs
Poliovirus type-specific intestinal antibody responses were 
evaluated in 156 stool samples from 12 adult placebo-arm 
subjects participating in the mOPV1 challenge trial. Total 
IgA was successfully detected in stool samples from all 12 
participants. The median concentration of total IgA at 
baseline was measured to be 28 000 ng/mL (IQR: 14 000–
63 000). Pre-existing intestinal neutralising antibody 
titers specific to the three poliovirus serotypes were all 
measured to be ≤3.3 in the stool samples collected prior 
to challenge, and poliovirus types 1-specific, 2-specific 
and 3-specific stool IgA levels were undetectable for all 
participants at baseline.
Following challenge, the 12 subjects experienced 
sustained viral shedding that lasted for between 11 and 17 
days and reached a median peak log10 viral shedding titer 
of 5.0 CCID50 per gram of stool (IQR: 4.7–5.9) (figure 1). 
Despite substantial virus shedding, no corresponding 
intestinal IgA or neutralisation responses were observed. 
In the stool samples collected in the 6 weeks after chal-
lenge, poliovirus types 1-specific, 2-specific and 3-specific 
IgA remained below the limit of detection for all 141 
tested specimens. Similarly, poliovirus type 1-specific 
stool neutralising antibody titers remained low (ie, ≤18.4 
across all time points and individuals) (figure 2). Like-
wise, poliovirus types 2-specific and 3-specific neutralising 
antibody titers in the stool samples showed no substan-
tive changes postchallenge (ie, titers remained at ≤7.2 for 
type 2 and ≤21.2 for type 3 across all time points and indi-
viduals) (online supplementary file 1). In contrast, polio-
virus type 1-specific serum neutralising activity increased 
significantly after OPV1 challenge (p=0.002, Wilcoxon 
signed rank test), with a median fold-change of 32 (IQR: 
8–96) and a median day-45 serum neutralising antibody 
titer of 256 (IQR: 256–512) (figure 2). Further, whereas 
intestinal antibodies to all three types of poliovirus exhib-
ited low neutralising activity in stool samples at 45 days’ 
postchallenge (median, IQR for type 1: 1, 1–4.6; type 2: 
1.5, 1–2.7; type 3: 1, 1–1), neutralising antibodies were 
detectable in the stool samples for both RSV (median, 
IQR: 21.5, 15–50) and A/California/04/2009 H1N1 
influenza virus (median, IQR: 74, 31.5–90) (figure 3). 
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Figure 2 Subject-specific poliovirus type 1-specific serum IgA (dashed line) and stool neutralising antibody titers (solid line) 
at the time of mOPV1 challenge and in the 45 days after challenge in adults previously vaccinated with four doses of IPV in 
childhood (N=12). mOPV1, monovalent oral polio vaccine type 1.
Figure 3 Neutralising antibody titers for A/
California/04/2009 H1N1 influenza, respiratory syncytial virus 
(RSV) and poliovirus (PV) types 1, 2 and 3 in stool samples 
collected 45 days’ postchallenge with monovalent oral polio 
vaccine type 1 in adults previously vaccinated with four 
doses of IPV in early childhood (N=12).
The type of diet received did not alter any immunologic 
parameter measured.
dIsCussIon
With the declining circulation of wild polioviruses world-
wide, health systems are becoming increasingly reliant 
on IPV as the principal tool for achieving global polio 
eradication. Though it is well established that IPV-driven 
schedules are highly effective at minimising paralytic 
polio risks across the lifespan, the limited capacity of IPV 
schedules delivered in childhood to confer intestinal 
immunity capable of interrupting poliovirus transmission 
remains an important consideration for the global polio 
eradication strategy.28 Using samples collected from 
a subset of 12 placebo-arm participants administered 
mOPV1 in a randomised controlled trial of a potential 
polio antiviral, pocapavir,24 we investigated intestinal 
immunity to poliovirus in adult participants by meas-
uring poliovirus type-specific neutralising activity and 
IgA responses in faecal samples. In samples collected at 
baseline (ie, prior to mOPV1 challenge), we found no 
evidence of pre-existing intestinal immunity to any of the 
three poliovirus serotypes in this group of Swedish adults 
with a prior history of IPV immunisation in childhood. 
Surprisingly, we detected only minimal type 1-specific 
stool neutralisation and no stool IgA responses following 
live OPV challenge. Assuming that the assay performance 
in adult stool samples is robust, the results raise concerns 
about the effectiveness of OPV vaccination in boosting 
mucosal immunity among older individuals and, there-
fore, have potentially important implications for the 
planning of vaccine provisioning as part of the Global 
Polio Eradication Initiative’s outbreak control activities.
Our finding that IPV receipt in childhood was not asso-
ciated with detectable prechallenge levels of intestinal 
poliovirus-specific neutralising activity and IgA in adult-
hood aligns with prior OPV challenge studies as well as 
observational epidemiologic evidence. As part of a 1990 
American clinical trial in which children were vaccinated 
with an enhanced-potency IPV at 2, 4 and 18 months of 
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age prior to challenge with mOPV1, 68% of children 
had undetectable poliovirus type 1-specific stool IgA 
following the primary IPV vaccine series, while 63% went 
on to shed vaccine virus on challenge.29 Similarly, in a 
2010 Omani clinical trial in which infants were vaccinated 
with IPV at 2, 4 and 6 months and then challenged with 
mOPV1 at 7 months, 73% of the infants had undetect-
able (ie, <2) poliovirus type 1-specific stool neutralising 
titers following the primary IPV vaccine series,15 while 
63% went on to shed vaccine virus on challenge.30 Analo-
gous failures to induce poliovirus type 2-specific mucosal 
immunity by IPV have been observed as part of trials in 
Panama11 and Chile12 among infants who were vaccinated 
with three doses of IPV before challenge with mOPV2. 
Furthermore, in a faecal monitoring study conducted in 
response to the 2013 silent outbreak of wild poliovirus 
type 1 in Israel, 85% of faecal samples that were positive 
for virus were collected from children (<10 years of age) 
who had been previously vaccinated with at least three 
doses of IPV.31
The observation that, despite documented viral repli-
cation and sustained excretion, the Swedish study partic-
ipants failed to mount an intestinal antibody response 
to mOPV1 challenge was unanticipated and in marked 
contrast to the experiences of five OPV challenge studies 
in paediatric participants.10–12 15 29 For both of the afore-
mentioned mOPV1 challenge studies in the USA29 and 
Oman,15 rises in poliovirus type 1-specific intestinal 
immune markers (ie, IgA in stool specimens and neutral-
ising activity, respectively) were reported in the IPV recip-
ients following mOPV1 receipt. Further, in the mOPV2 
challenge studies in Panama11 and Chile,12 the poliovirus 
type 2-specific intestinal antibody responses appeared 
similar to the poliovirus type 1-specific antibody responses 
in the American and Omani studies and different from 
that observed in the current study. Specifically, infants 
with detectable viral shedding following mOPV2 chal-
lenge exhibited brisk intestinal antibody responses, with 
significant increases in poliovirus type 2-specific stool 
IgA and neutralising activity titers by 2 weeks’ postchal-
lenge. Parallel rises in poliovirus type 2-specific mucosal 
immune markers following mOPV2 challenge have also 
been reported among infants from Guatemala and the 
Dominican Republic who received a primary immunisa-
tion series of three doses of bivalent OPV (ie, targeting 
poliovirus types 1 and 3) plus one dose of IPV.10
Although the finding of an absence of an intestinal 
antibody response to mOPV1 challenge in adults was 
unexpected, there is some indirect evidence in the liter-
ature of an age-related diminution of intestinal immu-
nity to poliovirus. Surveillance data of viral excretion 
in Indian children under age 5 indicate that intestinal 
immunity in children vaccinated with OPV wanes within 
the first year after OPV exposure.32 Consistent with this 
model, an early report of British young men aged 16–18 
years found that 20% of the participants who had been 
previously vaccinated with OPV (ie, on average 5 years 
prior) excreted poliovirus type 1 on subsequent trivalent 
OPV challenge.33 Similarly, in a study of the induction of 
mucosal immunity by IPV boosting in adults aged 20–44 
years, investigators reported detecting poliovirus types 
1-specific, 2-specific and 3-specific IgA in stool samples 
from only three of nine adults who had received a primary 
vaccine series of OPV in childhood.5
We also found complementary evidence for the biolog-
ical plausibility of the observed phenomenon through 
further testing of available study samples. First, we 
observed that all 12 participants mounted serum neutral-
isation responses. Second, we were able to detect total 
IgA successfully in stool samples from each of the partic-
ipants. Although the total quantified concentrations of 
intestinal IgA in the adults were lower than that previously 
reported in studies of breastfed infants,12 the concen-
trations were similar to those observed among infants 
with mixed or formula feeding (data not shown). Third, 
although we considered other hypothetical explanations 
relating to the induction of a tolerance or senescence of 
the mucosal immune system in adulthood, we observed 
that the participants’ stool samples had neutralising 
activity against two other commonly circulating viruses, 
RSV and influenza.
Mucosal immunity to RSV and influenza has been 
demonstrated in the setting of natural infection and 
in response to immunisation with live and inactivated 
vaccines.34–37 Neutralisation of these viruses has been 
assessed in the past using mucosal specimens, including 
nasal washes, collected from the upper respiratory tract. 
Our data are the first to demonstrate neutralisation of 
RSV and influenza by samples from the gastrointestinal 
tract (eg, stool extracts). While our observations are 
preliminary and will require further study, this finding is 
consistent with the broad concept of a common mucosal 
immune system and the induction of virus-specific immu-
nity at sites distal from the location of primary infection.
Despite this being the first OPV challenge study that 
directly measured intestinal antibody responses to polio-
virus strains in adult populations, this investigation 
has limitations. By design, the mOPV1 challenge trial 
restricted enrollment to immune-competent individuals 
who were negative for serum poliovirus-specific IgA at 
baseline (as a control for potential past exposure to live 
poliovirus). While this selection criterion maximised the 
likelihood of mOPV1 replication on challenge, it limits 
the generalisability of our findings across the general 
population of adults and also potentially biases the 
study towards subjects who may have been incapable of 
mounting intestinal antibody responses to poliovirus. 
Notably, in contrast to the prior OPV challenge studies 
of IPV recipients, the setting in Sweden is unique in that 
routine childhood vaccination was historically done with 
IPV. The findings of this study, while consistent across all 
participants, are also constrained by the small number of 
study subjects.
Looking to the future, it will be valuable to validate 
these findings across different age ranges (ie, in cohorts 
of older children, adolescents and adults) and to explore 
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whether there could be any age-mediated restrictions to 
the amount of secreted IgA that is detectable in stool. The 
investigation should also be replicated across older indi-
viduals with different vaccine histories (ie, in participants 
who received OPV vaccination schedules in childhood) 
to determine whether the observed deficit in response 
could be influenced by prior vaccine experience. Further, 
as the primary site of poliovirus replication and immune 
response is in the small intestine, we have considered 
that IgA may be degraded by proteases while in transit 
through the adult intestinal tract, and as a result, the 
observation of a lack of poliovirus-specific intestinal anti-
body response is the subject of on-going experimentation 
in our laboratory. Further, it will be important to explore 
additional immunological responses (eg, cell-medi-
ated immunity) or body fluids (eg, saliva), which may 
contribute to the participants’ ability to control the chal-
lenge virus infections in the absence of a detectable anti-
body-mediated response in the intestinal mucosae.
In conclusion, the reported failure to detect an intes-
tinal antibody response to mOPV1 challenge in an adult 
population is intriguing and evokes questions about the 
nature and regulation of the mucosal immune response 
to serial poliovirus vaccination. These findings imply that 
existing OPVs may be less effective at inducing transmis-
sion-blocking intestinal antibody responses in IPV-vacci-
nated adults than they are in children. The findings also 
highlight the importance of considering the impact of 
existing and new polio vaccines (eg, novel live-attenuated 
OPVs)38 in terms of their ability to elicit mucosal immu-
nity and limit onwards transmission across a wide range 
of subjects.
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